Market Research Blog

[225 Pages Report] Steroid-free nasal sprays are medications that are directly delivered to nasal cavities with the avoidance of first-pass metabolism and also provide better bioavailability. It includes nasal antihistamine sprays, nasal decongestant sprays, nasal anticholinergic sprays, and nasal cromolyn sodium sprays.

As per Future Market Insights’ latest industry analysis, the global steroid-free nasal sprays market was valued at over US$ 7.75 Bn in 2021 and is expected to exhibit a CAGR of 6.3% over the forecast period, pushing the market size to US$ 14.9 Bn by 2032.

Data Points	Market Insights
Steroid-free Nasal Sprays Market Base Yea Value (2021)	US$ 7.7 Bn
Estimated Market Size (2022)	US$ 8.1 Bn
Projected Market Valuation (2032)	US$ 14.9 Bn
Value-based CAGR (2022-2032)	6.3%
Share of Top 5 Countries	57.9%

There is a subsequent rise in the prevalence of allergic rhinitis worldwide due to several risk factors including urbanization and environmental pollutants. According to a recent study conducted in 2022, allergic rhinitis affects about 25% to 40% of the population worldwide. It also states that approximately 80% of allergic rhinitis symptoms develop before the age of 20.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15127

Recently, there has been an increasing emphasis on mental illnesses due to the significant rise in cases of major depressive disorders. Among these, depression is a common mental disorder. According to WHO, approximately 280 million people of all ages suffer from depression.

Due to rising adverse effects of depression, manufacturers in the steroid-free nasal sprays market are focusing on introducing products that can be used for the treatment of these disorders in the most effective manner.

Moreover, an increased number of regulatory approvals have been observed in the steroid-free nasal sprays market which is propelling the launch of innovative products. Therefore, manufacturers in the market are focusing on getting regulatory approvals to improve sales in the market.

“Rising availability of generic nasal sprays, along with increasing promotional activities by manufacturers at online channels will boost sales of steroid-free nasal sprays over the assessment period,” says an FMI analyst.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15127

Key Takeaways:

• Based on product type, sales of nasal antihistamine sprays will increase at a 5.9% CAGR through 2032.
• The aqueous by formulation segment dominated the steroid-free nasal sprays market with around 4% share in 2021.
• In terms of distribution channels, demand in the institutional segment will grow at a 6% CAGR through 2032.
• North America accounted for the highest share of 6% of the global steroid-free nasal sprays market share in 2021.

Competition Landscape

Prominent players operating in the global steroid-free nasal sprays market are focusing on the development, launch, and approval of innovative products to improve their product portfolios. For instance:

• In February 2022, Glenmark Pharmaceuticals Limited along with SaNOtize Research & Development Corp. announced the launch of FabiSpray, the nitric oxide nasal spray for the treatment of COVID-19 in India.
• In March 2021, Cipla Limited announced that it has received final approval from the FDA for its abbreviated new drug application (ANDA) for Sumatriptan Nasal Spray, 20 mg which is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline’s Imitrex nasal spray.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the steroid-free nasal sprays market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032. The global steroid-free nasal sprays market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The steroid-free nasal sprays market is segmented into three parts based on the product (nasal antihistamine sprays, nasal decongestant sprays, nasal anticholinergic sprays, nasal cromolyn sodium sprays, and others), formulation (aqueous, suspension, nonaqueous-based solution, hydroalcoholic, emulsions, and dry powder/micro particles) and distribution channel- (institutional sales {hospitals, specialty clinics, community clinics, public health agencies, and others}, retail sales {retail pharmacy, drug stores, mail order pharmacy}), across seven key regions of the world.

Key Players :

• Janssen Pharmaceutical, Inc.
• Astra Zeneca Plc.
• Cipla Ltd.
• Glenmark Pharmaceuticals
• Glaxosmithkline Plc.
• Novartis International AG
• Procter & Gamble
• Sanofi S.A. (Sanofi-aventis LLC.)
• Boehringer Ingelheim GmbH
• AdvaCare Pharma
• Bayer AG (Bayer Consumer Health
• Covis Pharma S.a.r.l.
• Nipro Corporation (NIPRO JMI Pharma Ltd.)
• Viatris Inc. (Meda Pharmaceuticals Inc.)
• Perrigo Company plc
• AptarGroup, Inc.
• Berry Global, Inc.
• URSATEC GmbH
• Gerresheimer AG
• Avantor, VWR International, LLC
• Spectrum Laboratory Products, Inc.  (Spectrum Pharmacy Products)
• SKS Bottle & Packaging, Inc.
• Coster Tecnologie Speciali S.p.A

Request Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15127

Steroid-Free Nasal Sprays Market by Category

By Product:

• Nasal Antihistamine Sprays
• Nasal Decongestant Sprays
• Nasal Anticholinergic Sprays
• Nasal Cromolyn Sodium Sprays
• Others

By Formulation:

• Aqueous
• Suspension
• Nonaqueous-Based Solution
• Hydroalcoholic
• Emulsions
• Dry Powder/Micro Particles

By Distribution Channel:

• Institutional Sales
  • Hospitals
  • Specialty Clinics
  • Community Clinics
  • Public Health Agencies
  • Others
• Retail Sales
  • Retail Pharmacy
  • Drug Stores
  • Mail Order Pharmacy

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[280 Pages Report] As per Future Market Insights’ latest analysis, the global phakic intraocular lenses (IOL) market reached US$ 344.4 Mn in 2021. Sales are projected to grow at a 9.5% CAGR over the forecast period, with the market valuation reaching US$ 819.5 Mn in 2032.

Patients with high ametropia or contraindications to laser refractive surgery are treated with phakic intraocular lenses (pIOLs). The key aspect that makes these lenses ideal for use in young adults seeking ocular prescription independence is the preservation of accommodation, as lens extraction is not required.

Furthermore, as the number of people who are myopic has increased in recent years, this refractive correction option has become increasingly significant. Simultaneously, it is an important area of research in light of future estimates of the prevalence of simple myopia and, more importantly, severe myopia.

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15128

Because of the aesthetic and optical constraints of the conventional ophthalmic lens, as well as growing trend of contact lens overuse, phakic IOLs are a viable option for individuals with severe myopia.

Although phakic intraocular lenses have some benefits over laser refractive surgery, such as reversibility, enhanced optical quality in high ametropias, and a wider range of correction, etc., it is important to remember that it is a surgical procedure with all of the risks that are associated with intraocular surgeries, including severe complications including endophthalmitis.

Growing concerns with increasing ocular disease indication burden, high prevalence of diabetes and associated retinopathy, as well as the development of alternatives to removable spectacles and lenses for corrective vision are chief factors expected to drive the market.

“Advances in excimer laser procedures have presented a gateway into the development of implantable intraocular lenses with effective vision correction outcomes. Such developments are anticipated to auger well for the market over the forecast period,” says an FMI analyst.  

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-15128

Key Takeaways:

• Based on product type, the posterior chamber phakic IOL segment accounted for 0% of the total market share in 2021 and the trend is expected to continue through 2032.
• By indication, sales in the astigmatism segment will increase at a 8.5% CAGR over the assessment period.
• In terms of end user, the hospitals segment will remain most lucrative over the forecast period.
• The U.S. is expected to lead the North America phakic intraocular lenses market over the assessment period.
• Demand in China is expected to grow at a 10.5% CAGR through 2032.
• Germany will emerge as a lucrative pocket, with sales rising at a 9.3% CAGR over the forecast period.

Competition Landscape

Key players are investing in research and development to offer patient-specific and indication-specific pIOLs to enhance procedural outcomes. They are also focusing on new product launch activities, licensing of product sales within a specific region, as well as regulations associated with new device development and manufacturing. For instance:

• In January 2019, owing to the high regulatory standards, precision and quality requirements in Germany and Japan, Star Surgical announced expanded recommended diopter range for their EVO Visian ICL in both the countries.
• In December 2019, Johnson & Johnson Vision announced the Food and Drug Administration (FDA) approval and U.S. launch of TECNIS Toric II 1-Piece Intraocular Lens (IOL).

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/15128

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the phakic intraocular lenses (IOL) market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (posterior chamber phakic IOL, and anterior chamber phakic IOL), by indication (myopia, hyperopia, and astigmatism), by end user (hospitals, ophthalmology clinics, and ambulatory surgical centres), across seven key regions of the world.

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

[300+ Pages Report] The market for INR test metres is anticipated to reach US$ 1.3 billion by the end of 2022, growing at a CAGR of 6.3 percent, and surpassing US$ 2.4 billion by 2032. With a market share of approximately 79.7% in 2021, the devices segment dominated the global INR test metre market in terms of product type.

As per Future Market Insights, the global INR test meter market was around US$ 1.2 Bn in 2021, and is projected to exhibit a CAGR growth of close to 6.3% over the forecast period, exceeding valuation of US$ 2.4 Bn in 2032.

Patients with coagulopathic aberrations related to pathological conditions have a strong reliance on PT diagnostic platforms. Patients who take warfarin frequently have medical conditions that put them at high risk for severe illness, including hospitalization, intensive care admissions, and death, as per the Centers for Disease Control and Prevention.

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15124

With the emerging importance of utilizing point-of-care tests, the market for INT test meters is set to witness high demand during the forecast period (2022-2032). One of the primary factors driving the growth of the INR test mater market is rising prevalence of cardiovascular diseases and blood disorders across the globe.

Demand for INR test meters is expected to grow due to increased awareness of these disorders, which will improve diagnostic rates and preventive care management. Further, with favorable government funds and investments for acquiring and installing such medical devices in public healthcare facilities, the demand in the market is projected to surge through 2022 & beyond.

Key Takeaways from Market Study

• In terms of product, devices held approximately 7% of market value share in 2021, owing to their efficacy in delivering positive therapeutic outcomes.
• Based on end users, hospitals segment is expected to register a CAGR of 8% during the forecast period.
• North America is considered as the leading region with a value share of 6% in 2021, owing to high lifestyle associated disease cases, and rapid device approvals.
• The U.K. is expected to lead the growth in Europe INR test meter market backed by its development in healthcare infrastructure

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-15124

“Growing advancements of digital solutions for medical use is set to propel the sales of the INR test meter market across the globe,” says an analyst of Future Market Insights.

Market Competition

Key manufacturers in the INR test meter market are adopting strategic approaches such as mergers and research activities for revenue growth and product portfolio expansion. Producers are also engaged in several patent expiry mitigation approaches to further provide upgraded product lines, thus establishing a strong geographical outlook.

• In November 2021, CoaguSense Inc. incorporated a novel “Prothrombin Time Home Testing System” connected with MedM remote care platform.
• In May 2021, Biosynex acquired Avalun to become a European leader in rapid diagnostic testing.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/15124

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the INR test meter market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (device, lancet, and test strips), by end user (hospitals, speciality clinics, ambulatory surgical centres, and home care settings), across seven key regions of the world.

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[250 Pages Report] Global systemic lupus erythematous drugs market growth is fast in North American region and is estimated to project remarkable CAGR growth throughout forecast period. In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans according to Centers for Disease Control and Prevention (CDC). The second largest and fastest growing global systemic lupus erythematous drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double digit CAGR due to higher prevalence of SLE in Europe.

Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis, thrombosis, and myositis.

Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1149

It is also known as a disease of flare-ups and remissions and can range from mild to life threatening severity. It is also called as drug-induced lupus erythematosus due to common observation against drugs such as isoniazid, hydralazine and procainamide. Currently, there is no complete treatment for SLE. While only two biologic agents have been approved by FDA to treat SLE, synthetic drugs are still the mainstay of therapy in SLE. Based on available evidence, azathioprine and mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug in SLE because of the multiple beneficial effects of this agent.

Systemic Lupus Erythematous (SLE) Drugs Market: Drivers & Restraints

Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-1149

Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market.

Systemic Lupus Erythematous (SLE) Drugs Market: Segmentation

The global systemic lupus erythematous drugs market is classified on the basis of molecule and region.

Based on type of molecule, the global systemic lupus erythematous drugs market is segmented into the following:

Corticosteroids

Prednisone

Cortisone

Hydrocortisone

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

Over-the-counter NSAIDs include

Ibuprofen (Motrin)

Naproxen (Naprosyn)

Prescription versions include

Indomethacin (Indocin)

Nabumetone (RELAFEN)

Celecoxib (Celebrex)

Anti-Inflammatories

Aspirin

Acetaminophen (Tylenol)

For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1149

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Hydroxychloroquine (Plaquenil).

Cyclosporine (Gengraf, Neoral, Sandimmune)

Azathioprine (Azasan, Imuran)

Antimalarials

Chloroquine (Aralen)

Hydroxychloroquine (Plaquenil)

BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)

Belimumab (Benlysta)

Immunosuppressive Agents/Immune Modulators

Azathioprine (Imuran)

Methotrexate (Rheumatrex)

Cyclophosphamide (Cytoxan)

Anticoagulants

Low-dose aspirin

Heparin (Calciparine, Liquaemin)

Warfarin (Coumadin)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs